Debut has a new ingredient and is working with skin care brands on formulations.
The biotech beauty company is launching DermCeutical EDLTM, a topical bioactive ingredient that claims to deliver skin-tightening benefits.
Developed through Debut’s proprietary platform integrating AI, skin genomics and biotechnology, DermCeutical EDLTM biologically activates the cellular pathways targeted by in-office treatments, achieving clinically proven results in skin tightness and firmness, the company claims.
Related Articles
DermCeutical EDLTM activates dermal fibroblasts to boost elastin, the key skin-scaffolding protein essential for firmness. It also mitigates cellular stress by downregulating stress-related proteins and reversing adverse gene expression, promoting long-term dermal integrity and a visibly lifted appearance.
“Three years ago, we set out to try and create solutions that would work alongside injectables and doctor’s office treatments,” said Joshua Britton, chief executive officer of Debut. “We have spent years understanding how skin physically tightens and why you get jowls and the fat comes down. Once we understood it, we used our AI platform to screen through 50 billion ingredients to find this one.”
In a 12-week clinical study, DermCeutical EDLTM delivered clinically meaningful improvements across key skin metrics. Dermatologist-blinded assessments demonstrated a 100 percent fine-line improvement rate and a 73 percent improvement in skin sagging, compared to placebo. The ingredient rejuvenated aged cells by 31 percent, restoring skin structure and resilience for a more youthful appearance.
“We’ve started working with quite a few brands on this ingredient now,” Britton said. “They’re attacking it from two angles. Most are working with skin care, but some are starting to incorporate this into color products, like contouring products.”
He expects the first products featuring the ingredient to come to market this year.
In 2023, L’Oréal led a $40 million round of series B funding in Debut through its venture arm Bold. In 2024, Debut signed an agreement with L’Oréal to develop more than a dozen bio-identical ingredients that will replace conventionally sourced ingredients currently used in L’Oréal global beauty and personal care brands across skin, hair, color cosmetics and fragrance.
Later that year, Debut entered the contract manufacturing business, with the goal of bringing biotech ingredients to the masses. The business division harnesses end-to-end services, including novel ingredient discovery, pre-clinical testing, formulation development, quality control production, and access to Debut’s IP portfolio.
